2023
Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life
Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.Peer-Reviewed Original ResearchLethal prostate cancerSociodemographic factorsAdvanced CaPAdvanced diseaseYounger patientsProstate cancerHigher oddsAdvanced stageProstate-specific antigen (PSA) screeningCharacteristics of patientsNational Cancer DatabaseRetrospective cohort studySubset of patientsPatient sociodemographic factorsMultivariable logistic regressionPatients' health insuranceHighest income quartileCohort studyAdvanced cancerAntigen screeningMean ageInsurance statusCancer DatabaseCaP screeningSociodemographic disparities
2020
A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).
Ross A, Armstrong A, Pieczonka C, Bailen J, Tutrone R, Cooperberg M, Pavlovich C, Renzulli J, Haynes H, Sheikh N, Shore N. A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2020, 38: 321-321. DOI: 10.1200/jco.2020.38.6_suppl.321.Peer-Reviewed Original ResearchMetastatic castrate-resistant prostate cancerCD54 upregulationProstate cancerOverall survivalActive surveillanceCell countCastrate-resistant prostate cancerPeripheral blood mononuclear cellsEarly-stage prostate cancerAutologous cellular immunotherapyLarger immune responsesPhase III studyBlood mononuclear cellsStage prostate cancerTotal nucleated cell countNucleated cell countIII studyCellular immunotherapyMononuclear cellsTreatment weekProstate adenocarcinomaT cellsImmune responseTNC countProvent
2014
Extracellular vesicle-mediated reversal of taxane resistance and the malignant phenotype in prostate cancer.
Nadeem O, Mega A, Keller E, Renzulli J, Quesenberry P, Chatterjee D. Extracellular vesicle-mediated reversal of taxane resistance and the malignant phenotype in prostate cancer. Journal Of Clinical Oncology 2014, 32: e16028-e16028. DOI: 10.1200/jco.2014.32.15_suppl.e16028.Peer-Reviewed Original Research
2013
766 FEASIBILITY OF RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT IXABEPILONE FOR HIGH-RISK PROSTATE CANCER: A PHASE II CLINICAL TRIAL
Maddox M, Layton J, Taber A, Mega A, Renzulli J. 766 FEASIBILITY OF RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT IXABEPILONE FOR HIGH-RISK PROSTATE CANCER: A PHASE II CLINICAL TRIAL. Journal Of Urology 2013, 189: e314-e315. DOI: 10.1016/j.juro.2013.02.330.Peer-Reviewed Original Research1248 PROSTATE MRI TO EVALUATE EXTRA-CAPSULAR EXTENSION AND SEMINAL VESICLE INVASION IN PROSTATE CANCER IN A COMMUNITY SETTING
Bishop K, Layton J, Furman M, Maddox M, Grand D, Renzulli J, Mega A. 1248 PROSTATE MRI TO EVALUATE EXTRA-CAPSULAR EXTENSION AND SEMINAL VESICLE INVASION IN PROSTATE CANCER IN A COMMUNITY SETTING. Journal Of Urology 2013, 189: e510-e511. DOI: 10.1016/j.juro.2013.02.2602.Peer-Reviewed Original Research
2012
The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial.
Layton J, Plette A, Renzulli J, Miller E, Safran H, Mega A. The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: A phase I/II clinical trial. Journal Of Clinical Oncology 2012, 30: 158-158. DOI: 10.1200/jco.2012.30.5_suppl.158.Peer-Reviewed Original ResearchHigh-risk prostate cancerPhase I/II clinical trialsPathologic complete responsePositive surgical marginsWeekly ixabepiloneProstate cancerAdverse eventsPSA responseComplete responseSurgical marginsPSA valuesClinical trialsPositive regional lymph nodesCessation of chemotherapyPre-operative PSAPretreatment Gleason scorePhase II studyRisk prostate cancerHigh-risk diseaseRegional lymph nodesBiochemical recurrence rateMetastatic prostate cancerTime of reviewCT3 diseaseGleason 8